Study on anti-p53 antibodies in skin cancer patients
Author Information
Author(s): Moch C, Moysan A, Lubin R, Salmonière P de La, Soufir N, Galisson F, Vilmer C, Venutolo E, Pelletier F Le, Janin A, Basset-Séguin N
Primary Institution: Unité INSERM U532, Institut de Recherche sur la Peau, Hôpital Saint-Louis, Paris, France
Hypothesis
What is the prevalence of anti-p53 antibodies in skin carcinoma patients compared to a control group?
Conclusion
The study found a low prevalence of anti-p53 antibodies in skin carcinoma patients, despite a high rate of p53 mutations in these tumors.
Supporting Evidence
- Anti-p53 antibodies were detected in 2.9% of skin carcinoma cases.
- The prevalence of anti-p53 antibodies was higher in aggressive squamous cell carcinoma patients (8%) compared to basal cell carcinoma patients (1.5%).
- p53 protein stabilization was confirmed in 80% of the tumors studied.
Takeaway
The study looked at how many skin cancer patients have a specific antibody, and it found that not many do, even though their tumors often have mutations.
Methodology
A prospective study using ELISA to detect anti-p53 antibodies in skin carcinoma patients and comparing them to a control group.
Participant Demographics
105 skin carcinoma patients compared to 130 age- and sex-matched controls.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website